EyePoint, Inc.EYPTEarnings & Financial Report
Nasdaq · Health Care · Laboratory Analytical Instruments
EyePoint Pharmaceuticals Inc. is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery.
Revenue
$14.0M
Gross Profit
N/A
Operating Profit
$-16.4M
Net Profit
$-14.1M
Gross Margin
N/A
Operating Margin
-116.6%
Net Margin
-100.5%
YoY Growth
33.2%
EPS
$-0.32
EyePoint, Inc. Q4 FY2023 Financial Summary
EyePoint, Inc. reported revenue of $14.0M (up 33.2% YoY) for Q4 FY2023, with a net profit of $-14.1M (up 67.6% YoY) (-100.5% margin).
Key Financial Metrics
| Total Revenue | $14.0M |
|---|---|
| Net Profit | $-14.1M |
| Gross Margin | N/A |
| Operating Margin | -116.6% |
| Report Period | Q4 FY2023 |
EyePoint, Inc. Annual Revenue by Year
EyePoint, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $43.3M).
| Year | Annual Revenue |
|---|---|
| 2024 | $43.3M |
| 2023 | $46.0M |
| 2022 | $41.4M |
EyePoint, Inc. Quarterly Revenue & Net Profit History
EyePoint, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 FY2025 | $5.3M | -43.7% | $-59.4M | -1114.3% |
| Q1 FY2025 | $24.5M | +109.3% | $-45.2M | -184.8% |
| Q4 FY2024 | $11.6M | -17.4% | $-41.4M | -357.3% |
| Q3 FY2024 | $10.5M | -30.8% | $-29.4M | -279.0% |
| Q2 FY2024 | $9.5M | +4.1% | $-30.8M | -325.3% |
| Q1 FY2024 | $11.7M | +52.1% | $-29.3M | -250.6% |
| Q4 FY2023 | $14.0M | +33.2% | $-14.1M | -100.5% |
| Q3 FY2023 | $15.2M | +51.8% | $-12.6M | -83.0% |
Income Statement
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $15.2M | $14.0M | $11.7M | $9.5M | $10.5M | $11.6M | $24.5M | $5.3M |
| YoY Growth | 51.8% | 33.2% | 52.1% | 4.1% | -30.8% | -17.4% | 109.3% | -43.7% |
Balance Sheet
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $160.0M | $355.2M | $329.2M | $324.2M | $300.9M | $418.5M | $362.6M | $301.1M |
| Liabilities | $101.4M | $88.9M | $79.3M | $95.9M | $82.2M | $82.0M | $64.2M | $55.1M |
| Equity | $58.6M | $266.3M | $249.9M | $228.3M | $218.7M | $336.5M | $298.4M | $246.0M |
Cash Flow
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-15.2M | $-23.1M | $-31.2M | $-20.2M | $-39.0M | $-35.8M | $-53.1M | $-62.6M |